Literature DB >> 27816788

TLR4-HMGB1 signaling pathway affects the inflammatory reaction of autoimmune myositis by regulating MHC-I.

Zemin Wan1, Xiujuan Zhang2, Anping Peng3, Min He3, Zhenhua Lei4, Yunxiu Wang3.   

Abstract

OBJECTIVES: To analyze the effects of TLR4 on the expression of the HMGB1, MHC-I and downstream cytokines IL-6 and TNF-α, and to investigate the biological role of the TLR4-HMGB1 signaling pathway in the development of the autoimmune myositis.
METHODS: We built mice models with experimental autoimmune myositis (EAM) and used the inverted screen experiment to measure their muscle endurance; we also examined inflammatory infiltration of muscle tissues after HE staining; and we assessed the expression of MHC-I using immunohistochemistry. In addition, peripheral blood mononuclear cells (PBMC) were extracted and flow cytometry was utilized to detect the effect of IFN-γ on the expression of MHC-I. Furthermore, PBMCs were treated with IFN-γ, anti-TLR4, anti-HMGB1 and anti-MHC-I. Real-time PCR and western blotting were employed to examine the expressions of TLR4, HMGB1 and MHC-I in different groups. The ELISA method was also utilized to detect the expression of the downstream cytokines TNF-α and IL-6.
RESULTS: The expressions of TLR4, HMGB1 and MHC-I in muscle tissues from mice with EAM were significantly higher than those in the control group (all P<0.05). After IFN-γ treatment, the expressions of TLR4, HMGB1, MHC-I, TNF-α and IL-6 in PBMCs significantly increased (all P<0.05). The treatment of anti-TLR4, anti-HMGB1 and anti-MHC-I could significantly downregulate the expression of MHC-I (all P<0.05). In addition, anti-TLR4 and anti-HMGB1 significantly reduced the expression of TNF-α and IL-6 (all P<0.05).
CONCLUSIONS: The TLR4-HMGB1 signaling pathway affects the process of autoimmune myositis inflammation by regulating the expression of MHC-I and other pro-inflammatory cytokines. Copyright Â
© 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoimmune myositis; MHC-I; Proinflammatory cytokines; TLR4-HMGB1 signaling pathway

Mesh:

Substances:

Year:  2016        PMID: 27816788     DOI: 10.1016/j.intimp.2016.10.009

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  7 in total

Review 1.  Risk factors and disease mechanisms in myositis.

Authors:  Frederick W Miller; Janine A Lamb; Jens Schmidt; Kanneboyina Nagaraju
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

2.  High Mobility Group Box 1 Protein in Osteoarthritic Knee Tissue and Chondrogenic Progenitor Cells: An Ex Vivo and In Vitro Study.

Authors:  Gunar Wagner; Christoph Lehmann; Christa Bode; Nicolai Miosge; Andrea Schubert
Journal:  Cartilage       Date:  2019-03-26       Impact factor: 4.634

3.  Vitamin D reduces inflammatory response in asthmatic mice through HMGB1/TLR4/NF‑κB signaling pathway.

Authors:  Han Zhang; Nan Yang; Tianyue Wang; Bing Dai; Yunxiao Shang
Journal:  Mol Med Rep       Date:  2017-12-07       Impact factor: 2.952

Review 4.  Progressive Skeletal Muscle Atrophy in Muscular Dystrophies: A Role for Toll-like Receptor-Signaling in Disease Pathogenesis.

Authors:  Boel De Paepe
Journal:  Int J Mol Sci       Date:  2020-06-22       Impact factor: 5.923

5.  TLR expression in peripheral monocyte subsets of patients with idiopathic inflammatory myopathies: association with clinical and immunological features.

Authors:  Jiram Torres-Ruiz; Daniel Alberto Carrillo-Vazquez; Diana Marcela Padilla-Ortiz; Ricardo Vazquez-Rodriguez; Carlos Nuñez-Alvarez; Guillermo Juarez-Vega; Diana Gomez-Martin
Journal:  J Transl Med       Date:  2020-03-12       Impact factor: 5.531

Review 6.  The Role of HMGB1 in Rheumatic Diseases.

Authors:  Yuanji Dong; Bingxia Ming; Lingli Dong
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

Review 7.  High-Mobility Group Box-1 and Liver Disease.

Authors:  Harriet Gaskell; Xiaodong Ge; Natalia Nieto
Journal:  Hepatol Commun       Date:  2018-09-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.